Recent AIM newcomer Blue Prism (AIM: PRSM) has released a promising set of maiden results for the half year to April. Revenues grew by a handy 21 per cent and momentum seems to be accelerating with 33 new customers added to the 57 in place at the end of October.
Having turned most of its market cap into cash through the sale of its aerospace division, it’s no surprise that Avingtrans (AIM: AVG) has been a very defensive stock during the recent turmoil. We now have some more details on the return of cash to shareholders which was promised as part of the disposal.
Omega Diagnostics results looked positive and highlighted the progress being made in getting important new products to market. The investment to support those efforts will depress profits this year; but the market seems willing to look through this with Omega being a rare stock to be trading above its pre-Brexit level.
Stadium Group shares have been hit by a profit warning. This is a particular blow given the company’s progress in repositioning itself into a higher quality, design-led business.
Verona Pharma (AIM: VRP) has raised an impressive £42 million net of costs which will fund phase II trials for its RPL554 compound. This drug targets severe respiratory diseases, in particular the 65 million worldwide sufferers from COPD (chronic obstructive pulmonary disease).
It’s fair to say that buy-to-let landlords have been under George Osborne’s cosh. He’s introduced a raised stamp duty rate and withdrawn higher-rate tax relief. However, Belvoir Lettings has seen little change in the market as far as its core lettings agency business is concerned. Furthermore, the shares have responded positively to a major acquisition which makes Belvoir the largest UK lettings agent.